ClinicalTrials.gg
CompletedNCT01291004Updated Dec 8, 2021

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

A Phase 1 interventional study of Desogestrel/ethinyl estradiol and ethinyl estradiol and 28-day drospirenone oral contraceptive in Follicle Development, Ovarian Follicle and Follicle Count, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 2 sites in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-08.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.

02

Conditions studied

  • Follicle Development
  • Ovarian Follicle
  • Follicle Count
  • Follicle Size
  • Oral Contraceptive
03

In context

Lead sponsor

Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal, non-pregnant, non-lactating women age 18-35 years old
  • (BMI) ≥18 kg/m² and \<30 kg/m²
  • Regular spontaneous menstrual cycle
  • Others as dictated by Food and Drug Administration (FDA)-approved protocol

Exclusion criteria

Exclusion Criteria:

  • Any condition which contraindicates the use of combination oral
  • Known thrombophlebitis or thromboembolic disorders; known or suspected clotting disorders; thrombogenic valvulopathies or rhythm disorders
  • Migraine headaches with focal, neurological symptoms
  • Others as dictated by FDA-approved protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    28-day Desogestrel Oral Contraceptive

    Drug: Desogestrel/ethinyl estradiol and ethinyl estradiol

  • Active comparator
    28-day Drospirenone Oral Contraceptive

    Drug: 28-day drospirenone oral contraceptive

  • Active comparator
    28-day Levonorgestrel Oral Contraceptive

    Drug: 28-day levonorgestrel oral contraceptive

Interventions

  • DrugDesogestrel/ethinyl estradiol and ethinyl estradiol

    Drug pages: Desogestrel · Ethinyl Estradiol

    Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet

  • Drug28-day drospirenone oral contraceptive

    Drospirenone/ethinyl estradiol 0.3/0.02 mg

  • Drug28-day levonorgestrel oral contraceptive

    Levonorgestrel/ethinyl estradiol 0.1/0.02 mg

06

What researchers measure

Primary outcomes

  1. Evaluation of ovarian follicular development by the Hoogland and Skouby grading scale from baseline to week 16.

    Time frame: 16 weeks

  2. Change in serum Estradiol level from baseline to week 16.

    Time frame: 16 weeks

  3. Change in serum Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) levels from baseline to week 16.

    Time frame: 16 weeks

  4. Change in serum Progesterone level from baseline to week 20.

    Time frame: 20 weeks

Secondary outcomes

  1. Change from baseline to week 15 in Prothrombin fragment 1 + 2 levels.

    Time frame: 15 weeks

  2. Change from baseline to week 15 in D-dimer.

    Time frame: 15 weeks

  3. Change from baseline to end of week 15 in Plasmin-Antiplasmin complex

    Time frame: 15 weeks

  4. Change from baseline to week 15 in APTT and ETP based activated protein-C resistance (APC).

    Time frame: 15 weeks

  5. Change from baseline to week 15 in Fibrinogen.

    Time frame: 15 weeks

  6. Change from baseline to week 15 in Plasminogen, Factor II, Factor VII, Factor VIII, Protein C, and Free and Total Protein S.

    Time frame: 15 weeks

  7. Change from baseline to week 15 in Tissue Plasminogen Activator (t-PA).

    Time frame: 15 weeks

  8. Change from baseline to week 15 in Antithrombin.

    Time frame: 15 weeks

  9. Change from baseline to week 15 in Tissue Factor Pathway Inhibitor (TFPI).

    Time frame: 15 weeks

  10. Change from baseline to week 15 in Total Cortisol and Corticosteroid Binding Globulin (CBG).

    Time frame: 15 weeks

  11. Change from baseline to week 15 in Thyroid Stimulating Hormone (TSH).

    Time frame: 15 weeks

  12. Change from baseline to week 15 in Sex Hormone Binding Globulin (SHBG).

    Time frame: 15 weeks

  13. Return to ovulation rate at week 20.

    Time frame: Week 20

07

Study locations

2 sites
  • Teva Investigational Site 10119
    Philadelphia, Pennsylvania 19114, United States
  • Teva Investigational Site 10118
    Seattle, Washington 98105, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Mar 2012, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2011
First posted
Feb 7, 2011
StartActual
Jan 31, 2011
Primary completionActual
Mar 31, 2012
CompletionActual
Mar 31, 2012
Last update
Dec 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01291004
Responsible party
Sponsor
First posted
Feb 7, 2011
Start date
Jan 31, 2011
Primary completion
Mar 31, 2012
Completion
Mar 31, 2012
Last update
Dec 8, 2021

Study contacts

Teva Women's Health Research Protocol Chair
study chair · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desogestrel · Ethinyl Estradiol

Start the discussion